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Since CKD-712 has been developed as an anti-inflammatory 
agent, we examined the effect of CKD-712 during TLR4 
signaling. Using HEK293 cells expressing TLR4, CKD-712 
was pre-treated 1 hr before LPS stimulation. Activation of 
NF-κB was assessed by promoter assay. The activation of 
ERK, JNK, p38, IRF3 and Akt was measured by western 
blotting. CKD-712 inhibited the NF-κB signaling triggered 
by LPS. The activation of ERK, JNK, p38 or IRF3 was not in-
hibited by CKD-712. On the contrary the activation of these 
molecules was augmented slightly. The activation of Akt with 
stimulation of LPS was also enhanced with CKD-712 
pre-treatment at lower concentration, but was inhibited at 
higher concentration. We suggest that during TLR4 signaling 
CKD-712 inhibits NF-κB activation. However, CKD-712 
augmented the activation of Akt as well as Map kinases. 
Therefore, we suggest that CKD-712 might have a role as an 
immunomodulator.
[Immune Network 2011;11(6):420-423]
Immunomodulation  has  been  an  interesting  phenomenon 
among  immunologists  since  immunopotentiation  could  en-
hance  immunity  against  infection  or  tumors,  whereas  im-
munosupression  or  anti-inflammatory  manipulation  can  be 
used to control autoimmunity or diseases caused by aberrant 
or hyper-reactive immune responses. Sepsis is caused by hy-
per-responsiveness of the immune system, in which the mor-
tality rate is as high as 50% (1). In septic conditions, large 
amount  of  pro-inflammatory  cytokines  is  produced  rapidly. 
Therefore, the early innate response of the immune system 
to pathogens plays a critical role in septic conditions. Toll-like 
receptors (TLRs) are important pattern recognition receptors 
(PRRs) that participate in the innate immune response. TLR4, 
in  conjunction  with  CD14,  acts  as  the  receptor  for  lip-
opolysaccharide  (LPS),  a  component  of  Gram-negative  bac-
teria cell walls (2). TLR2 recognizes peptidoglycan and lip-
oteichoic acid (LTA) in Gram-positive bacteria cell walls (3). 
Activation of TLR2 or TLR4 through binding of their ligands 
leads to NF-κB activation and transcription of many genes, 
including  typical  pro-inflammatory  cytokines  such  as  tumor 
necrosis factor-α (TNF-α), interleukin- 1 (IL-1), and IL-6 as 
well  as  several  chemokines  that r e c r u i t  l e u k o c y t e s  i n t o  t h e  
site  of  inflammation  (4,5). 
    CKD-712  has  been  developed  as  an  anti-inflammatory 
agent  targeting  sepsis.  CKD-712  is  a  higenamine  derivative 
(1-alpha-naphthylmethyl-6,7-dihydroxy-1,2,3,4-tetrahydroiso-
quinoline), also referred to as YS 49. It has been shown that 
CKD-712 reduced NO production in macrophage cells and in-
creased  survival  rates  in  mice  after  LPS  treatment  (6,7). 
Furthermore inhibition of the Janus activated kinase (JAK)-2/ 
signal  transducer  and  activators  of  transcription  (STAT)-1 
pathway  by  CKD-712  has  been  reported  to  decrease  levels 
of iNOS, cyclooxygenase-2, and hemeoxygenase-1 in macro-
phage cells (8). More recently, CKD-712 was found to sup-
press the secretion of high-mobility group box 1 (HMGB-1) CKD-712 Regulates TLR4 Signaling
Jeonggi Lee, et al.
421 IMMUNE NETWORK http://www.ksimm.or.kr Volume 11 Number 6 December 2011
A
CKD-712 (μM)
B
CKD-712 (50 μM)
Figure 1. Effect of CKD-712 on TLR4 signaling. (A) To assess CKD-712 
toxicity HEK293-TLR4 cells (2×10
5) were cultured with CKD-712 for 
24 hrs and cell viability was determined by MTT assay. (B) To 
evaluate the effect of CKD-712 on NF-κB activation 2×10
5 HEK-TLR4
cells/well were seeded in 12-well plates and were cultured for 2 days. 
Then NF-κB promoter and pCMV β-gal vector were co-transfeceted 
overnight and CKD-712 (50μM) was pre-treated before LPS 
treatment. LPS was treated for 6 hrs. After measuring luciferase activity 
and β-galactosidase activity the luciferase activity was normalized for
transfection efficiency with the β-galactosidase activity.
CKD-712
Figure 2. Effect of CKD-712 on activation of MAP kinases and IRF3 
in TLR4 signaling. HEK293-TLR4 cells were stimulated with LPS (50 
ng/ml). Western blot was performed anti-ERK, anti-JNK, anti-p38 or 
anti-IRF3 antibodies. CKD-712 (50μM) was pre-treated 1 hr before 
LPS stimulation. Three independent experiments were performed and 
the representative data are shown.
via inhibition of phosphatidylinositol 3 (PI3K)-protein kinase 
C (PKC) signaling after LTA or LPS stimulation in macrophage 
cells  (9).
    In  this  study  we  attempted  to  determine  which  signaling 
pathway is affected by CKD-712 after TLR4 stimulation, since 
TLR4 is the major PRRs responsible in development of sepsis.
    HEK293-TLR4 cells (kindly provided by Professor Douglas 
T. Golenbock, Massachusetts University, USA) were cultured 
in 10% fetal bovine serum-RPMI1640 medium. HEK293-TLR4 
cells express MD2 and CD14 as w el l.  CK D -7 1 2 w as  k in d ly 
provided by ChongKunDang Pharm, Cheonan. LPS was pur-
chased from Sigma-Aldrich, St. Louis, MI, USA. To assess cell 
viability after treatment of CKD-712, cells were reacted with 
5  mg/ml  of  tetrazolium  salt  (3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide, MTT) (Sigma-Aldrich). After 3 
hrs of incubation (37
oC, 5% CO2) the medium containing MTT 
was removed and 200μl of DMSO was added into the well 
and the absorbance was measured at 540 nm. For the lucifer-
ase assay. 2×10
5 cells/well were seeded in 12-well plates and 
cultured for 2 days. NF-κB promoter and pCMV β-gal vec-
tor were co-transfected overnight, and CKD-712 was pre-treat-
ed before LPS treatment. LPS was treated for 6 hrs. Luciferase 
activity was measured by a Luciferase Reporter Assay System 
(Promega,  Madison,  WI,  USA)  and  β-galactosidase  activity 
was  measured  with  O-nitrophenyl-β-D-galactopyranoside 
(Sigma-Aldrich), as the substrate. Luciferase activity was nor-
malized  for  transfection  efficiency  with  the  β-galactosidase 
activity. Western blotting was done using anti-TLR4, anti-ERK, 
anti-p38, anti-JNK, anti-IRF3 or anti-Akt antibodies as well as 
control antibodies. All of the antibodies were purchased from 
Cell  Signaling  Technology  (Beverly,  MA,  USA).
    First, we determined the optimal concentration of CKD-712 
in HEK293-TLR4 cells. When treated with CKD-712 for 24 hrs 
the cell viability was 50% at 100μM and 40% at 200μM (Fig. 
1A). Next, HEK293-TLR4 cells were treated with LPS and NF-
κB activation was measured. CKD-712 was pre-treated 1 hr 
before stimulation of LPS. We found that 50μM of CKD-712 
inhibited NF-κB activation in TLR4 signaling. When treated 
with 50μM of CKD-712, NF-κB activation decreased to less 
than  100,000  RIU  (25  ng/ml  of  LPS)  and  200,000  RIU  (50 
ng/ml of LPS) when compared to 200,000 RIU and 500,000 
RIU,  respectively  in  control  groups  (Fig.  1B).
    Next,  we  investigated  whether  treatment  with  CKD-712 CKD-712 Regulates TLR4 Signaling
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Figure 3. Effect of CKD-712 on Akt 
activation in TLR4 signaling. HEK293-
TLR4 cells were stimulated with LPS
(50 ng/mL) and western blot was 
performed with anti-Akt antibodies. 
CKD-712 (50 or 100μM) was pre- 
treated 1 hr before LPS stimulation. 
Two independent experiments were
performed and the representative 
data are shown. The density was 
measures by densitometry and 
relative ratio of p-Akt/Akt in study 
groups was calculated based on the
p-Akt/Akt of control group as 1.0.
modulates MAP kinaseactivation. After stimulation with LPS, 
CKD-712 did not inhibit activation of ERK, JNK or p38 kinase 
in  HEK293-TLR4  cells  (Fig.  2).  Rather,  pre-treatment  with 
CKD-712  delayed  activation  of  these  kinases.  As  shown  in 
Fig. 3, MAP kinases were phosphorylated 15∼30 min follow-
ing stimulation with LPS, after which activation subsided in 
60 min. However, CKD-712 treatment extended the activation 
of ERK and JNK, which were found to be activated 60 min 
after TLR4 stimulation (Fig. 2). Phosphorylation of IRF3 was 
not inhibited and showed a sustained activation like the MAP 
kinases (Fig. 2). Interestingly, the activation of Akt was aug-
mented slightly with pre-treatment of CKD-712 (50μM) after 
LPS  stimulation  (Fig.  3,  left).  But  higher  concentration  of 
CKD-712 (100μM) inhibited the activation of Akt completely 
(Fig.  3,  right). 
    W i t h  t h e  b r i e f  d a t a  p r e s e n t e d  h e r e ,  w e  s u g g e s t  t h a t  
CKD-712  activated  Akt  and  MAP  kinases  after  TLR4  stim-
ulation  at  50μM.  Emerging  evidence  has  shown  the  ex-
istence  of  a  close  relation  between  TLRs  and  the  PI3K/Akt 
pathway.  One  of  the  early  evidences  demonstraetd  that 
PI3-kinase is involved in TLR4-mediated cytokine expression 
in mouse macrophages (10). Even in non-immune cells, such 
as,  in foam  cells, binding of  LPS  and  TLR4  increases  Nox1 
expression  through  the  phospholipase  A2  β-Akt  signaling 
pathway (11). Another paper reporting that HMGB-1 induced 
migration of vascular smooth muscle cells in the TLR4-depen-
dent PI3K/Akt pathway also suggests a strong involvement of 
PI3K/Akt  in  the  TLR4  signaling  pathway  (12). 
    But the PI3K-Akt-mTOR-p70 S6k pathway is also known to 
be a negative regulator of MyD88-dependent intracellular sig-
nals after TLR stimulation. TLR4-mediated signaling leads to 
rapid activation of PI3K and phosphorylation of Akt, a down-
stream target of PI3K in mouse macrophages, in which the 
sustained  interaction  of  MyD88/PI3K  with  the  TLR4  intra-
cellular  “signaling  platform”  negatively  regulates  further 
MyD88 dependent signaling (13). The administration of the 
T L R 2  l i g a n d ,  P a m 3CSK4,  was  found  to  significantly  increase 
the levels of phosphorylation of Akt, which lead to significant 
protection in a cerebral injury model, suggesting that the PI3 
kinase-Akt pathway is involved with TLR2 signaling as well 
as TLR4 signaling (14). More recently the association of en-
dogenous TBK1 and Akt was observed in macrophages when 
stimulated with poly (I：C) and LPS, showing that Akt activa-
tion mediated by TBK1 contributes to TLR3 and TLR4-medi-
ated  immune  responses  (15). 
  The effect of CKD-712 on phosphorylation of Akt depends 
on the cell types. In immune cells, CKD-712 inhibits Akt acti-
vation in macrophages (9) and human endothelial cells (15). 
But in rat heart muscle cells, CKD-712 enhances Akt activa-
tion  to  prevent  myocardical  ischemia  and  further  inflam-
mation (16). Our data show that in HEK293 cells, CKD-712 
at low concentration augments the activation of Akt, whereas 
high  concentration  of  CKD-712  has  an  inhibiting  effect. 
Therefore pharmaceutical agents regulating the PI3-Akt path-
way  may  be  used  as  immunomodulators  in  the  innate  im-
mune response. Although the mechanism of the augmented 
activation of Akt by CKD-712 and the inhibition of NF-κB 
activation have yet to be clarified, CKD-712 still has a poten-
t i a l  a s  a n  i m m u n o m o d u l a t o r .  
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